George Fritsma

MS, MLS, Lab Scientist, Educator, Author

George Fritsma is a medical laboratory scientist, educator, and author. George contributed five chapters to Keohane EM, Butina MM, Mirza KM, Walenga JM: Rodak’s Hematology; Clinical Principles and Applications, Seventh Edition, 2025, Elsevier; and is the co-author of Bennett A, Fritsma GA, Ernst DJ: Quick Guide to Blood Collection Edition 2, 2016, Marques MB, Fritsma GA: Quick Guide to Coagulation Testing Edition 3, 2015, and Reddy V, Marques MB, Fritsma GA: Quick Guide to Hematology Testing Edition 2, 2013, along with three additional titles, all published by AACC Press. He is a consultant in the Laboratory Medicine Department of Pathology at the University of Alabama at Birmingham. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

September 2026 QQ: Anticoagulant Therapy for LAC Patients with VTE

Our September 2026 Quick Question is a poll that asks: In your facility, what AC is used for LAC patients with VTE? Anti-Xa DOAC Anti-IIa DOAC Warfarin Aspirin None AC therapy is indicated for VTE, including VTE and fetal loss associated with the presence of chronic LAC in the plasma. The commonly used anti-FXa DOACs […]

Comments (1)

Anticoagulant Therapy

Heparin Re-exposure in HIT Patients

Obtain this article about HIT from your local medical library: Caudill EB, Kim JH, Kanaan DM, Sylvester KW, Pimentel LY, Kim CS, Connors JM. Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia. J Thromb Haemost. 2026 Aug 3:S1538-7836(26)00484-8. doi: 10.1016/j.jtha.2026.07.024. PMID: 42546848. Objective To evaluate heparin re-exposure practices and safety in patients with […]

Comments (0)

Anticoagulant Therapy

Women and Girls With Hemophilia and Hemophilia Carriers

This open-access article details ISTH guidance in managing hemophilia in women and girls: Srivaths L, Ardila J, Fijnvandraat K, van Galen K, James P, Larson J, Shapiro S, Sidonio R, Escobar M. The diagnosis and evaluation of women and girls with hemophilia and hemophilia carriers: guidance from the SSC of the ISTH. J Thromb Haemost. […]

Comments (0)

Bleeding Disorders

Can AI Replace Clinical Prediction Scores in Thrombophilia?

Here is an open-access that compares the efficacy of AI with traditional clinical prediction scores for thrombophilia: Danilatou V, Arachchillage DJ. Beyond accuracy: why replacing traditional scores with AI in thrombosis care creates new ethical and regulatory obligations. Semin Thromb Hemost. 2026 Sep 3. doi: 10.1055/a-2943-7750. PMID: 42692078. Abstract Clinical prediction scores have been central […]

Comments (0)

Thrombophilia

Study Results: Novel Thrombin Generation Assay Monitors Emicizumab and Octocog Alfa

Here are the open-access results of a study testing the efficacy of a novel intrinsic trigger reagent (platelet-poor plasma [PPP] Reagent INT) for monitoring emicizumab and octocog alfa: Urlings EH, Heubel-Moenen FCJI, van Oerle R, et al. Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A. […]

Comments (0)

Bleeding Disorders

A Haematologica Review of all Hemophilia Rebalancing Therapy Efforts

Here is an open-access article describing all efforts to develop effective rebalancing therapy, including Latarcibart®, a MOAB that suppresses PS, not previously described in FF: Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica. 2025 Dec 1;110(12):2902-2912. doi: 10.3324/haematol.2025.288245. PMID: 40820726; PMCID: PMC12666285. Abstract Treatment options for patients with hemophilia […]

Comments (0)

Bleeding Disorders

Monitoring ADAMTS13 Deficiency: An Expert Rev. Hematology Review

Here is a current open-access article about ADAMTS13 deficiency: Binder NB, Depasse F, Spannagl M, et al. Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach. Expert Rev Hematol. 2026 Sep;19(9):1037-1057. doi: 10.1080/17474086.2026.2702550. PMID: 42461718. Abstract Introduction: ADAMTS13, a crucial enzyme in hemostasis that specifically cleaves von Willebrand factor […]

Comments (0)

Bleeding Disorders

Addendum to QQ September 2026: Dr. Favaloro's Reference

The article cited by Dr. Favaloro in his comment appended to the September 2026 QQ introduction is open access. Click here for the complete text: Favaloro EJ, Pasalic L. Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. Res Pract Thromb Haemost. 2022;6:e12676. doi: 10.1002/rth2.12676. PMID: 35316943; PMCID: PMC8922544. Abstract Background Lupus anticoagulants (LA) are […]

Comments (0)

Blog

PT/INR and PTT Therapeutic Levels

From Jessica Warner, Kettering Health: Hi George, I was wondering whether there has ever been a discussion about evaluating these ranges and whether there’s a consensus on what they should be. I have been in my job for 12 years and never looked at them to change them until an AC at another health system […]

Comments (0)

Anticoagulant Therapy

September 2026 Cheat Sheet

Click here for our September 2026 Cheat Sheet. If you would like to receive your push copy of the monthly Cheat Sheet, please complete the form on the right. The push copy offers links to our August posts.

Comments (0)

Cheat Sheets

Questions or Comments?

Email George